Huiming Peng1, Tao Peng1, Jianguo Wen1, David A Engler1, Risë K Matsunami1, Jing Su1, Le Zhang1, Chung-Che Jeff Chang1, Xiaobo Zhou2. 1. Center for Bioinformatics & Systems Biology and Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA, Department of Radiology, The Methodist Hospital Research Institute, Houston, TX 77030, USA, Department of Pathology, The Methodist Hospital Research Institute, Houston, TX 77030, USA, Proteomics Programmatic Core Laboratory, The Methodist Hospital Research Institute, Houston, TX 77030, USA, College of Computer and Information Science, Southwest University, Chongqing 400715, China, Department of Pathology, Florida Hospital, Orlando, FL 32803, USA. 2. Center for Bioinformatics & Systems Biology and Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA, Department of Radiology, The Methodist Hospital Research Institute, Houston, TX 77030, USA, Department of Pathology, The Methodist Hospital Research Institute, Houston, TX 77030, USA, Proteomics Programmatic Core Laboratory, The Methodist Hospital Research Institute, Houston, TX 77030, USA, College of Computer and Information Science, Southwest University, Chongqing 400715, China, Department of Pathology, Florida Hospital, Orlando, FL 32803, USACenter for Bioinformatics & Systems Biology and Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA, Department of Radiology, The Methodist Hospital Research Institute, Houston, TX 77030, USA, Department of Pathology, The Methodist Hospital Research Institute, Houston, TX 77030, USA, Proteomics Programmatic Core Laboratory, The Methodist Hospital Research Institute, Houston, TX 77030, USA, College of Computer and Information Science, Southwest University, Chongqing 400715, China, Department of Pathology, Florida Hospital, Orlando, FL 32803, USA.
Abstract
MOTIVATION: p38 mitogen-activated protein kinase activation plays an important role in resistance to chemotherapeutic cytotoxic drugs in treating multiple myeloma (MM). However, how the p38 mitogen-activated protein kinase signaling pathway is involved in drug resistance, in particular the roles that the various p38 isoforms play, remains largely unknown. METHOD: To explore the underlying mechanisms, we developed a novel systems biology approach by integrating liquid chromatography-mass spectrometry and reverse phase protein array data from human MM cell lines with computational pathway models in which the unknown parameters were inferred using a proposed novel algorithm called modularized factor graph. RESULTS: New mechanisms predicted by our models suggest that combined activation of various p38 isoforms may result in drug resistance in MM via regulating the related pathways including extracellular signal-regulated kinase (ERK) pathway and NFкB pathway. ERK pathway regulating cell growth is synergistically regulated by p38δ isoform, whereas nuclear factor kappa B (NFкB) pathway regulating cell apoptosis is synergistically regulated by p38α isoform. This finding that p38δ isoform promotes the phosphorylation of ERK1/2 in MM cells treated with bortezomib was validated by western blotting. Based on the predicted mechanisms, we further screened drug combinations in silico and found that a promising drug combination targeting ERK1/2 and NFκB might reduce the effects of drug resistance in MM cells. This study provides a framework of a systems biology approach to studying drug resistance and drug combination selection. AVAILABILITY AND IMPLEMENTATION: RPPA experimental Data and Matlab source codes of modularized factor graph for parameter estimation are freely available online at http://ctsb.is.wfubmc.edu/publications/modularized-factor-graph.php.
MOTIVATION:p38 mitogen-activated protein kinase activation plays an important role in resistance to chemotherapeutic cytotoxic drugs in treating multiple myeloma (MM). However, how the p38 mitogen-activated protein kinase signaling pathway is involved in drug resistance, in particular the roles that the various p38 isoforms play, remains largely unknown. METHOD: To explore the underlying mechanisms, we developed a novel systems biology approach by integrating liquid chromatography-mass spectrometry and reverse phase protein array data from human MM cell lines with computational pathway models in which the unknown parameters were inferred using a proposed novel algorithm called modularized factor graph. RESULTS: New mechanisms predicted by our models suggest that combined activation of various p38 isoforms may result in drug resistance in MM via regulating the related pathways including extracellular signal-regulated kinase (ERK) pathway and NFкB pathway. ERK pathway regulating cell growth is synergistically regulated by p38δ isoform, whereas nuclear factor kappa B (NFкB) pathway regulating cell apoptosis is synergistically regulated by p38α isoform. This finding that p38δ isoform promotes the phosphorylation of ERK1/2 in MM cells treated with bortezomib was validated by western blotting. Based on the predicted mechanisms, we further screened drug combinations in silico and found that a promising drug combination targeting ERK1/2 and NFκB might reduce the effects of drug resistance in MM cells. This study provides a framework of a systems biology approach to studying drug resistance and drug combination selection. AVAILABILITY AND IMPLEMENTATION: RPPA experimental Data and Matlab source codes of modularized factor graph for parameter estimation are freely available online at http://ctsb.is.wfubmc.edu/publications/modularized-factor-graph.php.
Authors: Jeffrey C Silva; Marc V Gorenstein; Guo-Zhong Li; Johannes P C Vissers; Scott J Geromanos Journal: Mol Cell Proteomics Date: 2005-10-11 Impact factor: 5.911
Authors: K Podar; Y T Tai; F E Davies; S Lentzsch; M Sattler; T Hideshima; B K Lin; D Gupta; Y Shima; D Chauhan; C Mitsiades; N Raje; P Richardson; K C Anderson Journal: Blood Date: 2001-07-15 Impact factor: 22.113
Authors: Teru Hideshima; Klaus Podar; Dharminder Chauhan; Kenji Ishitsuka; Constantine Mitsiades; Yu-Tzu Tai; Makoto Hamasaki; Noopur Raje; Hiromasa Hideshima; George Schreiner; Aaron N Nguyen; Tony Navas; Nikhil C Munshi; Paul G Richardson; Linda S Higgins; Kenneth C Anderson Journal: Oncogene Date: 2004-11-18 Impact factor: 9.867
Authors: Constantine S Mitsiades; Nicholas Mitsiades; Vassiliki Poulaki; Robert Schlossman; Masaharu Akiyama; Dharminder Chauhan; Teru Hideshima; Steven P Treon; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson Journal: Oncogene Date: 2002-08-22 Impact factor: 9.867
Authors: Umesh T Sankpal; Susan B Ingersoll; Sarfraz Ahmad; Robert W Holloway; Vadiraja B Bhat; Jerry W Simecka; Liz Daniel; Ekamber Kariali; Jamboor K Vishwanatha; Riyaz Basha Journal: Tumour Biol Date: 2016-08-31
Authors: Daniel J de Klerk; Mark J de Keijzer; Lionel M Dias; Jordi Heemskerk; Lianne R de Haan; Tony G Kleijn; Leonardo P Franchi; Michal Heger Journal: Methods Mol Biol Date: 2022
Authors: Thomas E Yankeelov; Gary An; Oliver Saut; E Georg Luebeck; Aleksander S Popel; Benjamin Ribba; Paolo Vicini; Xiaobo Zhou; Jared A Weis; Kaiming Ye; Guy M Genin Journal: Ann Biomed Eng Date: 2016-07-06 Impact factor: 3.934